Valeant says Philidor pharmacy shutting down as it cuts ties

Margin Pressures Could Weigh on CVS Health (CVS) Shares; Oppenheimer Cuts Price Target to $115

Oppenheimer maintained an Outperform rating on CVS Health (NYSE: CVS), and cut the price target to $115.00 (from $122.00), following the company's 3Q earnings results. CVS reported 3Q revenue of $38.6B vs. consensus $37.9B. Adj. EPS was $1.29, in line with consensus $1.29. Analyst Mohan Naidu believes that the margin outlook and lack of clarity on organic growth in... More

Leerink Partners Would Buy CVS Health (CVS) on Current Weakness

Leerink Partners reiterated an Outperform rating and $125.00 price target on CVS Health (NYSE: CVS) following the company's 3Q earnings and conference call. Management highlighted that the core business continues to grow at a healthy rate. While 2016E EPS guidance is below consensus expectations, management reiterated that their longterm adjusted EPS growth... More

Bill Ackman said Valeant Pharma (VRX) worth $180-$240 Near-Term, $262-$350 Long-Term

On the Valeant Pharma (NYSE: VRX) call, Bill Ackman said Valeant worth $180-$240 and worth $262-$350 longer term (2020).

Evercore ISI's Raffat Provides Thoughts on Valeant Pharma (VRX)

Evercore ISI's Umer Raffat weighed in on Valeant Pharma (NYSE: VRX) following press reports last night on Philidor's drug dispensing practices and news this morning that Valeant is severing all ties to Philidor is a step in the right direction.

Raffat said he... More

Valeant Pharma (VRX) to Sever Ties with Philidor

Valeant Pharma (NYSE: VRX) announced that it is severing all ties with Philidor Rx Services, LLC, and that Philidor has informed Valeant that it will shut down operations as soon as possible, consistent with applicable laws.

"The newest allegations about activities at Philidor raise additional questions about the company's business practices," said J. Michael Pearson, Valeant's... More